CagriSema Phase 3 Results: What 22.7% Weight Loss Means
A medication I have been following for a while just reached a much more important milestone.
Novo Nordisk has released headline Phase 3 results from REDEFINE 1, a large study of CagriSema—the once-weekly combination of the amylin analogue cagrilintide and the GLP-1 medication semaglutide.
The number getting attention: 22.7%
In the analysis estimating what would happen if participants remained on treatment, average weight reduction at 68 weeks was 22.7% with CagriSema. That compared with 16.1% with semaglutide 2.4 mg, 11.8% with cagrilintide 2.4 mg, and 2.3% with placebo.
In the analysis that counted outcomes regardless of treatment adherence or rescue therapy, average weight reduction with CagriSema was 20.4%, compared with 3.0% with placebo.
Another number caught my attention: 40.4% of participants receiving CagriSema reached at least 25% weight loss in the on-treatment analysis.
The flexible dosing detail matters
REDEFINE 1 allowed dose adjustments rather than forcing every participant to remain at the maximum dose. At week 68, only 57.3% of participants in the CagriSema group were on the highest dose.
I think that makes the data more interesting, not less. Real clinical care is rarely about racing every patient to a maximum number. Tolerability, response, nutrition, and individual goals all matter.
What about side effects?
The most common adverse effects were gastrointestinal and were generally described as mild to moderate and diminishing over time. That is consistent with the types of issues already familiar in incretin-based treatment.
What does this mean for FDA timing?
A successful pivotal Phase 3 study is one of the major pieces needed before a company can ask the FDA to review a new medication. REDEFINE 1 is not an FDA decision by itself, but it moves CagriSema much closer to the point where the full clinical package can be assembled for regulatory review.
There are still additional data and development steps ahead. But this is the point in a drug-development story where 'interesting molecule' starts turning into 'potential future treatment option.'
What I am watching next
I want to see the full peer-reviewed Phase 3 publication, the results in people with type 2 diabetes, and what the eventual FDA submission looks like. This is no longer just an early pipeline story.
Comments